<DOC>
	<DOCNO>NCT02823691</DOCNO>
	<brief_summary>This Pilot , One-arm , Open-label , Prospective Study evaluate Safety Lanreotide 120 mg ATG combination Metformin patient advance progressive GI lung carcinoid . The patient population include patient histologically document diagnosis Well differentiate NET , G1-G2 accord last WHO Classification criterion GI lung NET carcinoid .</brief_summary>
	<brief_title>The MetNET-2 Trial</brief_title>
	<detailed_description>This study strategically position medical treatment safety efficacy context , Lanreotide safely effectively use combination agent , like Metformin . Aim study verify safety concomitant administration Lanreotide 120 mg ATG Metformin advance , progress gastro-intestinal lung carcinoid patient , accurately monitor patient tolerability point view study long .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Adult patient ( male female , age &gt; 18 year ) Patient advance disease , resectable . The evaluation unresectable disease perform surgeon multidisciplinary Milan ENETS Center Excellence tumour board Fondazione IRCCS Istituto Nazionale dei Tumori Milano . Patients histologically document diagnosis advance well differentiate ( G1 G2 ) GI lung carcinoid , define accord last WHO Classification criterion NET Tumor tissue available analysis Measurable disease disease progression 6 month study inclusion ( accord RECIST v 1.1 ) , document appropriate imaging Patient receive prior treatment surgery chemotherapy somatostatin analogue mTOR inhibitor systemic antineoplastic/target therapy Functioning nonfunctioning NETs Type2 Diabetic normoglycaemic patient Documented Octreoscan/PET Ga68 uptake/IHC stain SSTR2 receptor , within 6 month study entry Basal blood test : Counts neutrophil absolute value &gt; 1.5 x 103 / L Platelet count &gt; 100 x 103 / L Hemoglobin &gt; 9 g/dl Total Bilirubin &lt; 1.5 time upper limit normal AST , ALT &lt; 2.5 time upper limit normal Alkaline phosphatase &lt; 2.5 time upper limit normal Values serum creatinine &lt; 1.5 mg / dl . CCr ≥ 60 mL / min ECOG performance status ≤ 2 Life expectancy &gt; 12 month Written inform consent Female subject childbearing potential ( surgically sterile 2 year postmenopausal ) must use medically accept method contraception must agree continue use method duration study least 60 day participation study . Acceptable method contraception include double barrier method [ i.e . condom occlusive cap ( diaphragm cervical/vault cap ) ] spermicide , intrauterine device ( IUD ) , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method . Male subject female partner childbearing potential must use medically accept method contraception must agree continue use method duration study 60 day participation study . Exclusion Criteria Surgery perform within 28 day prior begin study treatment Brain metastasis spinal cord compression Type1 Diabetes Clinically significant cardiovascular disease , cardiovascular accident occur less 6 month , unstable angina , congestive heart failure grade great equal II ( accord classification New York Heart Association NYHA ) series cardiac arrhythmia require treatment Uncontrolled high blood pressure , atrial fibrillation Cardiovascular , lung , kidney hepatic disorder treated/controlled Cirrhosis , acute hepatitis chronic active hepatitis Metabolic disorder , clinical examination laboratory investigation contraindicate use drug study , patient high risk complication treatment Active uncontrolled severe infection Patients condition metabolic acidosis , acute chronic , include ketoacitosi History POTUS ( alcohol abuse ) , habitual intake alcohol ( ≥ 3 glass alcoholic drink / day ) sufficient cause hepatotoxicity Severe state dehydration Prolonged fast History immunosuppression , include positive HIV test Previous concomitant oncological pathology , except : basal cell skin cancer , situ , long every cancer patient diseasefree least 5 year Serious neurological psychiatric disorder Pregnancy lactation Patients use appropriate method contraception specify inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>NETs</keyword>
</DOC>